BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 24565969)

  • 1. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR
    Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S
    Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the Overcoming EGFR
    Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
    ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
    Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W
    Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of new thieno[2,3-
    Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
    Future Med Chem; 2023 Jul; 15(13):1167-1184. PubMed ID: 37529910
    [No Abstract]   [Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1/2 inhibitors.
    Xing K; Zhang H; Wang S; Li J; Mu Z; Zhang L; Zuo S; Wang Y; Li S; Wu B; Jing Y; Wen J; Liu D; Huang M; Zhao L
    Eur J Med Chem; 2024 Jun; 272():116499. PubMed ID: 38759457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor.
    Wang Y; Liu Y; Zhang Y; Zhang Z; Xu L; Wang J; Yang Y; Hu B; Yao Y; Wei M; Wang J; Tang B; Zhang K; Liu S; Yang G
    Eur J Med Chem; 2024 May; 271():116395. PubMed ID: 38626523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
    Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
    J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors.
    Wallace-Povirk A; Tong N; Wong-Roushar J; O'Connor C; Zhou X; Hou Z; Bao X; Garcia GE; Li J; Kim S; Dann CE; Matherly LH; Gangjee A
    Bioorg Med Chem; 2021 May; 37():116093. PubMed ID: 33773393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.
    Gangjee A; Kurup S; Ihnat MA; Thorpe JE; Disch B
    Bioorg Med Chem; 2012 Jan; 20(2):910-4. PubMed ID: 22204741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors.
    Lamie PF; Philoppes JN
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):864-879. PubMed ID: 32208772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decade's overview of 2-aminothiophenes and their fused analogs as promising anticancer agents.
    Darwish DG; El-Sherief HAM; Abdel-Aziz SA; Abuo-Rahma GEA
    Arch Pharm (Weinheim); 2024 Jun; 357(6):e2300758. PubMed ID: 38442316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator.
    Karati D; Mukherjee S; Roy S
    Med Oncol; 2024 Mar; 41(4):84. PubMed ID: 38438564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship.
    Yadav TT; Moin Shaikh G; Kumar MS; Chintamaneni M; Yc M
    Front Chem; 2022; 10():861288. PubMed ID: 35769445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTS: a pharmaceutical target seeker.
    Ding P; Yan X; Liu Z; Du J; Du Y; Lu Y; Wu D; Xu Y; Zhou H; Gu Q; Xu J
    Database (Oxford); 2017 Jan; 2017():. PubMed ID: 31725865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
    Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Biological Activity of Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine Derivatives as Anti-Inflammatory Agents.
    Zhang Y; Luo L; Han C; Lv H; Chen D; Shen G; Wu K; Pan S; Ye F
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29137170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors.
    Zaro BW; Whitby LR; Lum KM; Cravatt BF
    J Am Chem Soc; 2016 Dec; 138(49):15841-15844. PubMed ID: 27960302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
    Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
    Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
    Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.